147 related articles for article (PubMed ID: 24378095)
21. [Two patterns of mediastinal lymph node resection for non-small cell lung cancer of stage IIIA: survival analysis of 219 cases].
Zhang GQ; Han F; Gao SL; A DL; Pang ZL
Ai Zheng; 2007 May; 26(5):519-23. PubMed ID: 17672944
[TBL] [Abstract][Full Text] [Related]
22. The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.
Kim SH; Cho BC; Choi HJ; Chung KY; Kim DJ; Park MS; Kim SK; Chang J; Shin SJ; Sohn JH; Kim JH
Lung Cancer; 2008 Jun; 60(3):393-400. PubMed ID: 18155802
[TBL] [Abstract][Full Text] [Related]
23. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
[TBL] [Abstract][Full Text] [Related]
24. [Could plasma D-dimer levels be a predictive marker for prognosis in lung cancer?].
Kurt B; Kar Kurt Ö; Kalaycı D; Tuğ T; Talay F
Tuberk Toraks; 2013; 61(4):269-74. PubMed ID: 24506741
[TBL] [Abstract][Full Text] [Related]
25. [Clinical characteristics and prognosis of large cell lung cancer].
Chen C; Chen P; Zhang CC; Li N; Jin ZL; Li K
Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):932-4. PubMed ID: 21223803
[TBL] [Abstract][Full Text] [Related]
26. [Clinical significance of C-reactive protein in patients with stage I non-small cell lung cancer].
Shen L; Li ZM; Lu S
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):442-6. PubMed ID: 21875485
[TBL] [Abstract][Full Text] [Related]
27. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
29. [Establishment and evaluation of a prognostic prediction model for patients after complete resection of non-small cell lung cancer and multidisciplinary therapy].
Wei WD; Fu JH; Lin P; Li XD; Yang H; Rong TH; Chen LK
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):672-5. PubMed ID: 19173908
[TBL] [Abstract][Full Text] [Related]
30. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
31. [Multivariate survival analysis of 899 patients with non-small cell lung cancer after complete resection].
Wei WD; Wen ZS; Su XD; Lin P; Rong TH; Chen LK
Ai Zheng; 2007 Nov; 26(11):1231-6. PubMed ID: 17991324
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
[TBL] [Abstract][Full Text] [Related]
33. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.
Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
Lung Cancer; 2007 Jun; 56(3):363-9. PubMed ID: 17306906
[TBL] [Abstract][Full Text] [Related]
34. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
[TBL] [Abstract][Full Text] [Related]
36. The prognostic value of D-dimer in lung cancer.
İnal T; Anar C; Polat G; Ünsal İ; Halilçolar H
Clin Respir J; 2015 Jul; 9(3):305-13. PubMed ID: 24720709
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
38. Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients.
Guadagni F; Ferroni P; Basili S; Facciolo F; Carlini S; Crecco M; Martini F; Spila A; D'Alessandro R; Aloe S; Cerasoli V; Del Monte G; Mariotti S; Mineo TC; Roselli M
Lung Cancer; 2004 Jun; 44(3):303-10. PubMed ID: 15140543
[TBL] [Abstract][Full Text] [Related]
39. [Impact of TNM staging and treatment mode on the prognosis of non-small cell lung cancer].
Yu DP; Bai LQ; Xu SF; Han M; Wang ZT
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):465-8. PubMed ID: 19950561
[TBL] [Abstract][Full Text] [Related]
40. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
